CC BY
20
Evaluation of the results of treatment in patients with locally common forms of ovarian cancer.
Conclusions:
1. According to the X-ray, CT and MRI studies indicated that patients with middle and old age is a characteristic type of lesion polysegmental vertebrae and intervertebral discs;
2. The correct choice of surgical approach based on neurological disorders and on the basis of MRI studies of
patients with herniated discs promotes earlier restoration of the biomechanics of the spine and the regression of neurological symptoms.
3. We believe that patients elderly optimal surgical approach to the vertebral canal is hemilaminectomy that gives complete decompression of the dural sac and the spine.
References:
1. Abdurazakov A. U., Esmembetov I. N. Treatment of lumbar degenerative disc disease different types of traction//Health of Kazakhstan. - 1991. - № 11. - P. 59.
2. Gongalsky V. V. Electrophysiological evaluation of neurological manifestations of violations of the topography of the vertebral motor segment//Orthopedics, Traumatology and Prosthetics. - 2008. - № 11. - P. 43-46.
3. Korzh N. A., Prodan A. I., Baris A. E. Degenerative diseases of the spine and their structural and functional classification//Ukrainian neurosurgical Journal. - 2004. - № 3. - P. 71-80.
4. KorkunoffA. L. Surgical treatment of diseases degengerative lumbar spine in elderly persons. Abstract of diss. ... Can. Med. Sc. - M., 2010.
5. PovoroznyukV. V. Pain in lower back//Medix magazine. Anti-Aging. - 2009. - № 2(08). - P. 68-78.
6. Simonovic A. E., Fomichev N. G., Gunter V. E., Krutko A. V., Baykalov A. A. The use of implants made ofporous NiTi (NI-TI) for decom-pressive-stabiliziruyushih operations in lumbar osteochondrosis//Akt. vopr. trauma. and Areas Behavioral. - Bishkek, 1999. - P. 154-155.
7. Simonovic A. E., Morkin S. P., Baykalov A. A., Hrapov D. V. Treatment of lumbar spine degenerative lesions using dynamic interspi-nous implant//Spine Surgery. - 2007. - № 1. - P. 21-28.
8. Tikhodeev S. A., Putilov V. V., Ivanov T. Bone grafting with operations using anterolateral approaches in the treatment of degenerative disc disease of the lumbar spine//Trauma. and Areas Behavioral. Russia. - 2006. - № 2. - S. 283-284.
9. Sorokovikov V. A., Gorbunov A. V., Koshkareva Z. V., Bruchanov V. G., Pozdeyeva N. A. The classification of spinal stenosis in the lumbar spine//Bulletin ESSC RAMS. - 2010. - № 2(72). - P. 243-246.
10. Khudaiberdiyev K. T., Igamnazarov J. J., Khamidov M. Sh., Karimov A. G., Hoshimov U. U. Features ofMRI diagnosis of degenerative diseases of the spine in the elderly//Central Asian Medical Journal. - 2009. - Volume XV, № 3. - P. 78-79.
11. Khudyaev A. T., Lyulin S. V., Shchurova E. N. Percutaneous endoscopic discectomy method in the treatment of patients with degen-erative-dystrophic lesions of lumbar spine//Spinal Surgery. - 2006. - № 2. - P. 16-21.
12. Arunkumar M. J. High cervical and Lumbar canal Stenosis ofVaried Etiology: A Case Report/M. J. Arunkumar, V. Rajshekhar//Neu-rol India. - 2002. - vol. 50. - P. 81-83.
13. Iguchi Tetsuhiro. Minimum 10-Year Outcome of Decompressive Laminectomy for Degenerative Lumbar Spinal Stenosis//Bone joint Surg. - 2001. - Vol. 50. - P. 24-26.
14. Konno S. A. Diagnostic support tool for lumbar spinal stenosis: a self-administered, self-reported history questionnaire./Konno S., Kiku-chi S., Tanaka Y., Yamazaki K., Shimada Y., Takei H., Yokoyama T., Okada M., Kokubun S.//BMC Muscul. Disord. - 2007. - Vol. 30. - P. 102.
15. Richard W. Spinal stenosis and Neurogenic Claudication//Lippincott-Reven Publishers. - 1996. - Vol. 21. - P. 2046-2052.
Mamarasulova Dilfuzahon Zakirjanova, Head of the Department of Oncology, Radiology and Phtiziatry, Andijan State Medical Institute, Andijan, Uzbekistan
Ergasheva Zumrad Abdukaumovna, Head of the Department of Pharmocology
Ziyaeva Surayo Tahirovna, Doctor-intern of Andijan Region Oncologycal Dispancery
Yakubbekova Sohiba Sadikovna, Master degree Andijan State Medical Institute E-mail: ss-1961@mail.ru
Evaluation of the results of treatment in patients with locally common forms of ovarian cancer in Andijan Regional Oncological Dispensery
Abstract: The article deals with the treatment and the results of a locally common forms of ovarian cancer. The study included registered in Andijan Regional Oncological Dispensery histologically verified patients with ovarian cancer. The purpose of this section of our study is to evaluate the effectiveness of various schemes of neoadjuvant chemotherapy in combined treatment of patients with locally advanced ovarian cancer. Also, long-term treatment results are obtained depending on the different schemes poliochemotherapy.
Keywords: ovarian cancer, locally common forms of ovarian cancer, neoadjuvant chemotherapy, adjuvant chemotherapy, drug, treatment.
Section 5. Medical science
The main part of the malignant ovarian tumors constitute epithelial neoplasia, which at the time of diagnosis already have a common form of the disease [1].
Despite the use of different variants of combined and complex treatment, long-term results remain unsatisfactory. Little studied problems remain to study the role and place of neoadjuvant and adjuvant chemotherapy in combined treatment of ovarian cancer (OC) [2; 3].
Standard treatment in recent years is the use of platinum drugs in combination with other cytostatics. The data obtained in this matter are contradictory and differ from each other depending on the circuit and the chemotherapy regimen [4; 5].
The emergence of new drugs had an impact on results of treatment of ovarian cancer, especially in locally advanced form. This is confirmed by the statistics of the American Cancer Society, showed an increase in 5-year survival in ovarian cancer with 30 % in the 60s to 50 % in the 90s [6; 7].
The aim of the research — to improve the results of treatment of patients with locally common forms of OC in terms of Andijan Regional Oncological Dispensery (AROD).
Materials and methods
We studied the incidence of ovarian cancer based on age in the Andij an region, which were registered in AROD. All outpatient card accounts of patients with OC from 2013 to 2015 inclusive were investigated. For 3 years it was taken on account of 169 patients with OC, but with locally advanced forms of OC have held 44 (26 %) patients. The results of their own research in the years 2013-2015 with AROD happened rejuvenation of OC in the Andijan region, compared with the data for 20 years, when the bulk of this disease was old age. The highest incidence rates are observed in the older age groups. The allocation ofpatients over the age ofmost ofthem were between the ages of 41-50 years 44 patients (28 %), 51-60 years, 39 patients (26 %) and older than 60 years — 45 patients (30 %).
As can be seen from the chart, with rate incidence at 4150 years — 44 patients (28 %) and older than 60 years — 45 patients (30 %), which amounted to (58 %). The lowest rates were in 1730 years, 19 patients (6 %) and 31-40 years, 23 patients (10 %), which amounted to (16 %). Up to 20 years, the probability of OC is very low.
Results and discussion. To conduct this study, all the selected patients had locally advanced form of OC and were divided into groups depending on the treatment carried out by them. The first group consisted of 21 (47.7 %) and the second (control) group of 23 (52.3 %) of patients with OC. All patients had locally advanced form, which reacted III stage of the process. All patients underwent ultrasound study and computed tomography. Each group of patients were divided into two groups according to the treatment.
Patients Ith A subgroup consisting of 10 persons (22.4 %) had a laparotomy with biopsies followed rate poliochemotherapy (PCT) scheme ATS, which is a combination of cisplatin at a dose of 75 mg/m2 intravenously (w/w) at 1 day, doxorubicin — 40.0 mg/m2/day at 1 and cyclophosphamide — 600 mg/m 2/day at 1.
I B subgroup of patients consisted of11 persons (25 %) received cytoreductive surgery + ATS PCT scheme, which is a combination
of cisplatin at a dose of 75 mg/m 2 intravenously (w/w) at 1 day, doxorubicin — 40.0 mg/m 2 in/in 1 day and cyclophosphamide — 600 mg/m 2/day at 1.
Patients II A subgroup consisted of10 people (22.4 %) was conducted laparotomy + carboplatin — 450 mg. per day + 1 cc (pacli-taxel) (175 mg/m 2) + cc + progesterone scheme THT.
Patients II B subgroup consisted of 13 people (29.5 %) was performed cytoreductive surgery + carboplatin — 450 mg. per day + 1 cc (paclitaxel) (175 mg/m 2) + cc + progesterone scheme THT.
After the treatment, we observed long-term results of our patients survival in months (Table 1).
Table 1. - Survival rates by month depending on prognostic factors of patients receiving chemotherapy according to the scheme
Survival Months Group I (21 man - 47.7 %) II group (23 man - 52.3 %)
I (A) 10 (22.4 %) I (B) 11(25 %) II (A) 10 (22.4 %) II (B) 13 (29.5 %)
6-12 7 (15.9 %) 6 (13.6 %) 3 (6.81 %) 3 (6.81 %)
13-24 3 (6.81 %) 4(9.09 %) 5 (11.4 %) 6 (13.6 %)
25-36 - 1 (2.27 %) 2 (4.54 %) 4 (9.09 %)
Analysis of the data shows that the 1-year mortality in group I was — 13 (29.5 %), while it turned out much lower than in group 2 deaths within 1 year, which amounted to 6 (13.62 %) patients.
By comparing the 3-year survival of patients in group 1 received treatment scheme cytoreductive surgery+ATS PCT scheme, which is a combination of cisplatin at a dose of 75 mg/m 2 intravenously (w/w) at 1 day, doxorubicin — 40.0 mg/m 2/in 1 day and cyclophosphamide — 600 mg/m 2/day in 1 to 3 years survived only 1 (2.27 %) patients, where as in the 2 (control) patients in the treatment group with the circuit cytoreductive surgery + carboplatin — 450 mg. cc
1 day + paclitaxel — 175 mg/m 2 cc + progesterone + scheme THT survived to 36 months in 6 patients, which accounted for 13.63 %.
Conclusions:
1. Taking into account the age of the patients registered in AROD for 2013-2015 year, we found that the peak incidence of locally advanced forms of OC accounts for premenopausal and menopausal periods, age was 41-50 years (28 %) and older than 60 years (30 %). The total number was (58 %).
2. Carrying out the treatment in patients with locally OC scheme cytoreductive surgery + II line chemotherapy with carboplatin scheme — 450 mg. cc 1 day + paclitaxel — 175 mg/m 2 cc + progesterone + scheme THT survival was much higher 6 (13.63 %) patients, while in group 1 patients received treatment scheme cytoreductive surgery + ATS PCT scheme, which is a combination of cisplatin at a dose of 75 mg/m 2 intravenously (w/w) at 1 day, doxorubicin — 40.0 mg/m 2/day at 1 and cyclophosphamide — 600 mg/m 2/day in 1 to 3 years survived only one patient (2.27 %). It follows that the benefit of treatment with locally OC forms use
2 lines of chemotherapy with endocrine therapy and THT ovarian cancer has a positive effect on the long-term survival of patients.
References:
1. Health of the Russian population and the performance of health institutions in 2000 statistical data. - M.: Min. of Health of the RF, 2001.
2. Kozachenko V. P. Treatment ofpatients with ovarian cancer//Rus. Med. Journal (in Russian). - 2003. - Vol. 11. - № 26. - P. 1458-1464.
3. Jemal A., Murray T., Samuels A. et al. Cancer Statistics//Cancer J Clin. - 2003. - Vol. 53. - P. 5-26.
4. Kharitonova T. V. Modern standards of treatment of ovarian cancer//Modern Oncology (in Rus.). - 2003. - Vol. 5. - № 2. - P. 44-47.
5. Cancer Incidence in Five Continents//IARC Sci Publ. Lyon. - 1997. - Vol. 7. - P. 143.
6. Guide chemotherapy of neoplastic diseases/Ed. NI Perevodchikova (in Russian). - M., 2005. - P. 273-289.
7. Bourne T. H., Reynolds K., Campbell S. Ovarian cancer screening//Curr-Opin-Radiol. - 1991. - Vol. 2. - № 2. - P. 216-224.
